小RNA
抗药性
药品
癌症研究
癌症
血管生成
基因
生物
生物信息学
医学
药理学
遗传学
作者
Fatemeh Najafi,Shohre Karimi Kelaye,Bahareh Kazemi,Zahra Foruzandeh,Farahnaz Allahverdizadeh,Sajjad Vakili,Kowsar Kiani Rad,Mahdi Derakhshani,Saeed Solali,Mohammad Reza Alivand
标识
DOI:10.1016/j.prp.2022.154130
摘要
However, advanced technologies have been developed in the treatment of various cancers, but the mortality rate from cancer is still very high. Drug resistance is a major problem for patients with cancer, which causes the treatment process to fail. In addition to inhibiting drug resistance, targeted therapy is also very important in treatment.Nowadays, miRNAs have gained increasing interest as they play a major role in both drug resistance and targeted therapy. MicroRNA (miRNA) is an important part of non-coding RNA that regulates gene expression at a post-transcriptional level. The prevailing studies about miRNA expression have been expanded into a variety of neoplasms. MiR-424 and miR-631 targets genes involved in various cellular processes and can participate in proliferation, differentiation, apoptosis, invasion, angiogenesis, and drug resistance and sensitivity.In this study, we focus on the role of miR-424 and miR-631 in many cancer types by displaying the potential target genes associated with each cancer, as well as briefly describing the clinical uses of miR-424 and miR-631 as a diagnostic and predictive tool in malignancies.
科研通智能强力驱动
Strongly Powered by AbleSci AI